Navigation Links
Abuse-Deterrent Formulations of Purdue's OxyContin and Endo Pharmaceuticals' Opana ER Have Not Increased PCPs' Comfort When Prescribing These Products for Chronic Pain

BURLINGTON, Mass., July 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite the replacement of Purdue Pharma's OxyContin and Endo Pharmaceuticals' Opana ER with abuse-deterrent formulations, surveyed primary care physicians (PCPs) do not feel more comfortable prescribing these products for the treatment of chronic pain. In contrast, the majority of surveyed pain specialists report that they are more comfortable prescribing OxyContin and Opana ER now that the products feature abuse-deterrent properties.

(Logo: )

The U.S. Physician & Payer Forum report entitled Chronic Pain: How Will U.S. Payers and Prescribers Shape Market Access for Recently Launched and Emerging Products? also finds that 57 percent and 53 percent of surveyed managed care organization (MCO) directors report that coverage of OxyContin and Opana ER has not changed as a result of the products' reformulation to be abuse-deterrent—suggesting that, in many patients, the cost to reimburse OxyContin and Opana ER may outweigh the advantages of the abuse-deterrent formulations. In cases where a non-abuse-deterrent generic opioid was available, MCO directors are likely to only reimburse an abuse-deterrent product in patients with a history of drug abuse—signaling that emerging abuse-deterrent formulations will still be subject to coverage restrictions.

The report also finds that cost will likewise be an important consideration for prescribing and reimbursement of new chronic pain therapies, most notably for Pfizer's novel anti-NGF therapy tanezumab. Seventy-four percent of surveyed PCPs and 48 percent of surveyed pain specialists who do not expect to prescribe tanezumab cite the high expected cost of the drug for the patient as a reason that they would be unwilling to prescribe the drug. As a biologic therapy, tanezumab is expected to be priced at a considerable premium over traditional oral analgesics.

"Although the responses of surveyed physicians suggest that efficacy and safety/tolerability are the most important factors influencing treatment decisions for chronic pain, these physicians anticipate that patient out-of-pocket costs and reimbursement constraints will directly influence their prescribing of emerging chronic pain therapies," said Decision Resources Principal Business Insights Analyst Natalie Taylor, Ph.D. "Even if an emerging therapy demonstrates significantly greater efficacy than the current standard of care for reducing pain, we find that both surveyed PCPs and pain specialists consistently assign lower anticipated patient shares to emerging therapies if the agents were to be covered by MCOs as non-preferred brands. However, emerging therapies that lower the overall long-term costs of treating chronic pain conditions may potentially secure more favorable reimbursement status from MCOs."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Collegium Announces Results of Chronic Pain Patient Survey - Confirms Significant Unmet Medical Need for a Differentiated, Abuse-Deterrent, Extended-Release Opioid
2. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
3. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
4. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
5. XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
6. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
7. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
10. Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013
11. GW Pharmaceuticals to Report Q3 2013 Results and Host Conference Call on 5 August, 2013
Post Your Comments:
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, ... Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility ... home to some of the world’s leading providers of cereal and other breakfast foods. ...
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
Breaking Medicine News(10 mins):